SCHEMBL1521380

SCHEMBL1521380

CNc1cc2c(cn1)CN(c1ccc(F)c(NC(=O)Nc3cnn(C(C)(C)C)c3)c1)C(=O)N2C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.36
FGFR1 P11362 1/20 0.36
MAPK8 P45983 3/20 0.35
MAPK10 P53779 3/20 0.35
BRAF P15056 7/20 0.34
RAF1 P04049 5/20 0.34
KRAS P01116 3/20 0.34
KIT P10721 1/20 0.34
PDGFRA P16234 1/20 0.34
MAP2K2 P36507 2/20 0.33
MAP2K1 Q02750 2/20 0.33
MAPK9 P45984 1/20 0.33
RPS6KA2 Q15349 1/20 0.33
RPS6KA3 P51812 2/20 0.32
MAP4K1 Q92918 1/20 0.32
ARAF P10398 1/20 0.32
KDM1A O60341 1/20 0.32
ATR Q13535 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521747 0.90 KIT (0.38) KDRFGFR1MAPK8MAPK10BRAF
SCHEMBL1521836 0.89 KDR (0.34) KDRFGFR1MAPK8MAPK10BRAF
SCHEMBL1521629 0.88 RAF1 (0.36) KDRFGFR1MAPK8MAPK10BRAF
SCHEMBL1521638 0.83 BRAF (0.47) KDRFGFR1BRAFRAF1KIT
SCHEMBL1521917 0.83 KDR (0.40) KDRFGFR1BRAFRAF1KIT
SCHEMBL1521794 0.82 MAPK14 (0.44) KDRBRAFRAF1KRASMAP2K2
SCHEMBL1521767 0.81 BRAF (0.53) KDRBRAFRAF1KRASMAP2K2
SCHEMBL1521947 0.79 RAB9A (0.41)
SCHEMBL1521898 0.79 FGFR4 (0.35) KDRFGFR1MAPK8MAPK10BRAF
SCHEMBL1521965 0.79 MAPK14 (0.51) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 KDR 500/4885FGFR1 577/4885MAPK8 174/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KDR 500/4885FGFR1 577/4885MAPK8 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.